Immuneering closed at $3.76 on Nov 4, up 2.17%, 54.9% below its 52-week closing high. Volume of 727.7K shares was 0.88× its 20-day average (close to normal).
Split-adjusted performance: -1.8% over one month, -27.6% over six months, -42.7% over one year.
Short interest was 16.3M shares at the Oct 15 settlement, up 5.4% from the prior report (29.2% of float, 20.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IMRXImmuneering | $3.76 | +2.17% | −27.6% | — | — | — | $243.5M | |
| LABStandard BioTools | $0.6160 | +0.85% | −36.4% | −0.9% | 69.6% | 1.8 | $243.1M | Compare |
| LFCRLifecore Biomedical | $6.44 | +0.31% | +29.8% | — | −20.9% | — | $244.1M | Compare |
| KRROKorro Bio | $16.62 | +4.79% | +24.6% | −100.0% | — | — | $244.7M | Compare |
| ABEOAbeona Therapeutics | $4.22 | −0.71% | −29.8% | +2745.0% | −177.4% | — | $241.3M | Compare |
| GLSIGreenwich LifeSciences | $16.35 | +2.70% | −29.1% | — | — | — | $240.0M | Compare |
| CAMPCAMP4 Therapeutics | $3.74 | −2.35% | −7.9% | +18.8% | −1884.8% | — | $234.7M | Compare |
| VNDAVanda Pharmaceuticals | $3.88 | +3.47% | −47.8% | +24.1% | −32.3% | — | $234.6M | Compare |
| SIGASIGA Technologies | $3.15 | +1.29% | −33.0% | −49.5% | 30.4% | — | $226.3M | Compare |
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
